Similarly, treatment with ATP-competitive mTOR kinase inhibitors (OSI-027, AZD2014 and AZD8055) has been shown to persistently reduce tau levels in induced pluripotent stem cell-derived neurons from other tauopathies [34]. Here, MAPT is linked to tauopathy.